Estimating the impact of direct acting antiviral therapy on the prevalence of hepatitis C virus infection using phylogenetics
Introduction: Australia has provided unrestricted subsidized access to direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection since 2016. Epidemiological surveillance estimates suggest prevalence of chronic HCV infection has declined since 2016, but these estimates are not sep...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Elsevier
2025-05-01
|
| Ráidu: | Virus Research |
| Fáttát: | |
| Liŋkkat: | http://www.sciencedirect.com/science/article/pii/S0168170225000437 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
